Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment
Biogen and Eisai's Alzheimer's drug Leqembi received full FDA approval, enabling broader Medicare coverage. Novavax's stock surged after amending its vaccine deal with Canada, involving a $349.6M payment. Caribou Biosciences gained from Pfizer's $25M investment, advancing its CAR-T cell therapy. Prothena secured a $55M deal with Bristol Myers Squibb for Alzheimer's treatment rights.
Reference News
AbbVie to acquire Cerevel Therapeutics for $8.7B, enhancing its neuroscience pipeline. FDA approves Novartis' Fabhalta for PNH and Lilly's Jaypirca for second leukemia indication. Pfizer halts phase III for danuglipron due to side effects. J&J forecasts sales growth, Roche to buy Carmot Therapeutics for obesity treatments.
Biogen and Eisai's Alzheimer's drug Leqembi received full FDA approval, enabling broader Medicare coverage. Novavax's stock surged after amending its vaccine deal with Canada, involving a $349.6M payment. Caribou Biosciences gained from Pfizer's $25M investment, advancing its CAR-T cell therapy. Prothena secured a $55M deal with Bristol Myers Squibb for Alzheimer's treatment rights.